Immorta Bio is an anti-aging company dedicated to solving the diseases associated with aging by treating aging itself as a disease.
Their mission centers on rejuvenating damaged or aged organs to a healthier state, thereby potentially extending human lifespan and improving quality of life. To achieve this, Immorta Bio develops personalized stem cell technologies that uses the body’s innate ability to heal and regenerate, aiming to restore youthful functionality to tissues and organs.
Immorta Bio’s mission and technologies aim to leverage your young stem cells and your enhanced immune cells to deal with cancers or diseases of aging the way your body dealt with them when you were young and healthy.
Feel welcome to share your own thoughts on this company in the comment section below as well. I will be happy to discuss and learn more about how you see their potential in this field.
The Solution
Immorta Bio’s therapeutic pipeline features two primary platforms as illustrated by the following overview from their official website:
StemCell Revivify: Personalized Regenerative Medicine
Immorta Bio’s StemCell Revivify platform focuses on creating Personalized Mesenchymal Stem Cells (pMSCs) from a patient’s own tissues.
These pMSCs are designed to produce higher levels of interleukin-35 (IL-35), a protein associated with enhanced immune regulation and tissue regeneration. Elevated IL-35 levels have been linked to improved survival in patients with liver failure, as the protein aids in reducing inflammation and promoting organ repair.
By using the body’s natural healing mechanisms, StemCell Revivify aims to rejuvenate damaged or aged organs, potentially reversing the effects of aging-related diseases. This personalized approach ensures compatibility and reduces the risk of immune rejection.
SenoVax: Targeted Senolytic Immunotherapy
SenoVax is Immorta Bio’s pioneering senolytic immunotherapy platform designed to target and eliminate senescent cells.
Senescent cells are cells that have ceased dividing and contribute to aging and tumor progression. By clearing these cells, SenoVax aims to transform the tumor microenvironment, enhancing the body’s immune response against cancer.
Recent preclinical studies have demonstrated the efficacy of SenoVax in various cancer models:
- Lung Cancer:
SenoVax enhanced anti-tumor immune responses, leading to significant tumor reduction in animal models. - Multiple Cancer Types:
Positive results were observed in lung, breast, pancreatic, and brain cancer experiments, showcasing the broad potential of SenoVax across different malignancies.
The Company
Immorta Bio was founded in 2023 by the Venvalo Group, and is headquartered in Miami, Florida.
In terms of funding and partnerships specific details nothing has been publicly disclosed.
Interestingly, Immorta Bio features their intellectual property portfolio on their official website, which contains 20 technology patents. These patents encompass various innovations in stem cell therapies and regenerative medicine.
If you want to learn more about Immorta Bio you can view their official website through this link.
Read about more anti-aging companies on this website through this link.
